Pratik Shah Buys 30,000 Shares of ARS Pharmaceuticals

Pratik Shah recently made a notable investment in ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) by purchasing 30,000 shares on June 24, 2026. This transaction adds to the activity surrounding the company's stock, which traded near $8.54 on Saturday.

Insider Buying and Selling at ARS Pharmaceuticals, Inc.

On June 24, 2026, several insiders, including Pratik Shah, each bought 30,000 shares of ARS Pharmaceuticals. These transactions were not part of any pre-planned trading program. Other insiders involved were Peter Thompson, Laura Shawver, Rajeev Dadoo, Brent Saunders, and Saqib Islam, all of whom made similar purchases.

Other Institutional Activity in ARS Pharmaceuticals

Institutional investors have also shown interest in ARS Pharmaceuticals. Rubric Capital Management LP increased its holdings by 1.8 million shares, resulting in a 29.0% increase, bringing its total to 8 million shares valued at approximately $64.2 million. Millennium Management LLC significantly boosted its position by 2.8 million shares, marking an 88.8% increase, with a total of about 5.98 million shares valued at $48 million. In contrast, BlackRock, Inc. slightly reduced its stake by 73,063 shares, decreasing its holdings by 1.4% to 5 million shares worth around $40.2 million.

ARS Pharmaceuticals, Inc. Stock Up 45.0%

Shares of ARS Pharmaceuticals traded near $8.54 on Saturday. The company has a market capitalization of roughly $848 million and a forward P/E ratio of -10.32, indicating it's not currently profitable. The stock's 52-week range spans from $6.66 to $18.90, with a 50-day moving average of $8.70 and a 200-day moving average of $9.36. The company maintains a strong current ratio of 4.94 and a quick ratio of 4.64, though it has a high debt-to-equity ratio of 279.24.

Analysts Set New Price Targets

On June 25, 2026, Leerink Partners maintained its 'buy' rating for ARS Pharmaceuticals, setting a price target of $24.00. Cantor Fitzgerald also maintained a 'buy' rating with a target of $30.00 as of May 28, 2026. Analysts generally hold a positive view of the company, with a consensus 'strong buy' rating and an average target price of $28.40.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing and commercializing treatments for severe allergic reactions. The company's primary product is Neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Founded in 2015, ARS Pharmaceuticals is led by CEO Richard E. Lowenthal and employs 154 people.

Bottom Line

Pratik Shah's purchase of ARS Pharmaceuticals shares highlights continued insider confidence in the company's prospects. Investors will be watching closely as the company continues to develop its innovative treatments for severe allergic reactions. As always, it's important to remember that insider transactions are disclosed after the fact and may not indicate current positions.